As Netflix and Warner Bros. executives defended their proposed deal before a Senate subcommittee, a promise of a 45-day theatrical window for Warner Bros. films was met with scrutiny from exhibition leaders, who argue critical details about volume, marketing, and the fate of the PVOD window remain ominously unclear.
The British Film Institute reports a historic high of £2.8 billion spent on feature film production in the UK last year, a 31% surge driven largely by major Hollywood shoots. However, domestic film investment remains a minor share, raising questions about the impact of recent tax incentives.
In an open letter to the British creative industry, Paramount CEO David Ellison details commitments for a potential Warner Bros. Discovery takeover, promising at least 30 annual theatrical releases and a staunchly competitive market stance, positioning the move as a counterweight to dominant streaming platforms.
Sony Group's entertainment giant reported a 12% year-over-year decline in fiscal third-quarter sales, dragged down by weaker theatrical and television production results, while its music and gaming divisions continued to show robust growth.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
Strong performance from PlayStation and image sensor divisions drove Sony's quarterly operating profit to $3.28 billion, prompting an upward revision of its full-year forecast, even as its Pictures business faced a quieter release schedule.
Amazon's acquisition of a documentary on the sitting First Lady has sparked debate over corporate influence, while analysts see potential long-term benefits far exceeding its box office performance.
In an open letter to the UK creative industry, Paramount CEO David Ellison outlines his vision for a combined Paramount-Warner entity, pledging sustained investment and theatrical support while sharply criticizing Netflix's rival bid as a threat to competition.
Disney's latest animated juggernaut isn't just a theatrical hit; it's a case study in how the company leverages blockbuster IP to drive growth across streaming, parks, and consumer products, creating a competitive moat that rivals struggle to breach.
Amazon MGM Studios’ controversial Melania Trump documentary scored a surprising $7 million debut—a record for a non-concert documentary in a decade—yet remains far from recouping its massive $75 million investment amid polarized audience interest and a challenging theatrical landscape.
Sony Group has detailed ambitious plans to revitalize and expand the iconic Peanuts brand across its global music, film, and distribution networks, following its recent majority stake acquisition. The move signals a new integrated chapter for Charlie Brown and Snoopy.
Sony Group has raised its full-year forecast after posting a 22% jump in operating income for the December quarter, driven by strong performance in music and gaming services, despite a double-digit decline in its film and television unit.
Investment firm Lake Street Capital Markets has lowered its price target for Aquestive Therapeutics to $6, down from $8, while maintaining a Buy rating. The adjustment follows the company's receipt of a Complete Response Letter from the FDA for its epinephrine film Anaphylm, delaying its potential market launch.
Former President Bill Clinton and former Secretary of State Hillary Clinton have agreed to sit for closed-door, filmed depositions later this month with the House Oversight Committee, averting a contempt of Congress vote.
Despite a Complete Response Letter for its epinephrine film Anaphylm, Aquestive Therapeutics receives a vote of confidence from Leerink Partners. The firm highlights a 'silver lining,' noting the FDA's requests appear addressable without major new studies, setting a defined, though delayed, route to potential U.S. approval.
The Walt Disney Company has named Josh D’Amaro, the architect behind its lucrative parks and experiences division, as its next Chief Executive. The move signals a strategic pivot towards operational stability and capital-intensive physical expansion, even as the entertainment giant continues to navigate the turbulent waters of streaming and film.
Marius Borg Høiby, the son of Norway's Crown Princess Mette-Marit, has pleaded not guilty to multiple counts of rape as his high-profile trial opens, facing a total of 38 charges including abuse and covert filming.
Aquestive Therapeutics faces a regulatory delay for its sublingual epinephrine film, Anaphylm, after the FDA raised concerns primarily about its packaging and labeling. The company views the issues as solvable and is moving forward with redesigns and new studies, aiming for a 2026 resubmission while advancing parallel filings abroad.
The FDA has issued a complete response letter for Aquestive's sublingual epinephrine film Anaphylm, requesting new human factors studies. The company aims to resubmit its application by Q3 2026 while advancing regulatory efforts in Europe and Canada.
Disney's first-quarter earnings call highlighted a landmark $10 billion in Parks revenue and strong film performance, while the looming CEO succession question lingered in the background.
